Financière de Tubize Valuation

Q: What is the Fair Price of TUBB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

TUBB (€114.8) is trading above our estimate of [[fair value]] (€24.86)

Is TUBB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TUBB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TUBB (€114.8) is trading above our estimate of fair value (€24.86)

Significantly Below Fair Value: TUBB is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TUBB?

Key metric: As TUBB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TUBB. This is calculated by dividing TUBB's market cap by their current earnings.
What is TUBB's PE Ratio?
PE Ratio	70.9x
Earnings	€90.02m
Market Cap	€6.38b

TUBB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does TUBB's PE Ratio compare to its peers?

The above table shows the PE ratio for TUBB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	26.1x
HIK Hikma Pharmaceuticals	19x	12.8%	UK£4.3b
GSK GSK	21.8x	21.9%	UK£54.8b
AZN AstraZeneca	31.3x	18.4%	UK£162.4b
ANCR Animalcare Group	32.1x	15.8%	UK£148.5m
TUBB Financière de Tubize	70.9x	n/a	€6.4b

Price-To-Earnings vs Peers: TUBB is expensive based on its Price-To-Earnings Ratio (70.9x) compared to the peer average (26.8x).

Price to Earnings Ratio vs Industry

How does TUBB's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: TUBB is expensive based on its Price-To-Earnings Ratio (70.9x) compared to the European Pharmaceuticals industry average (21.4x).

Price to Earnings Ratio vs Fair Ratio

What is TUBB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TUBB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	70.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate TUBB's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

1.3%

-23.5%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

-13.4%

17.3%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

1.0%

13.3%